You are here: Industry Insights > Epidyolex

News List

MHRA approves for Epidyolex® (cannabidiol) for TSC seizure treatment europeanpharmaceuticalreview
August 13, 2021
GW Pharmaceuticals received approval for Epidyolex®(cannabidiol) for the treatment of seizures linked to tuberous sclerosis complex (TSC) in the UK.
UK approval for Epidyolex to treat seizures from tuberous sclerosis pharmatimes
August 11, 2021
Jazz Pharmaceuticals subsidiary GW Pharmaceuticals has received approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for its cannabidiol Epidyolex as an adjunctive treatment of seizures associated with tuberous sclerosis ...
GW Pharma’s Epidyolex scores new EU indication pharmatimes
April 22, 2021
GW Pharmaceuticals’ Epidyolex has received approval from the European Commission (EC) for the treatment of seizures associated with tuberous sclerosis complex (TSC) – its third indication in Europe.
GW Pharmaceuticals Receives European Commission Approval for EPIDYOLEX® (cannabidiol) for the Treatment of Seizures Associated with Tuberous Sclerosis Complex americanpharmaceuticalreview
April 21, 2021
GW Pharmaceuticals plc, a world leader in discovering, developing and delivering regulatory approved cannabis-based medicines, today announces that the European Commission (EC) has approved the Type II variation application for EPIDYOLEX® ...
GW Receives Positive CHMP Opinion for EPIDYOLEX for TSC Seizures americanpharmaceuticalreview
March 04, 2021
GW Pharmaceuticals announced the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on the Company’s Type II variation application for EPIDYOLEX® (cannabidiol) as an adjunctive ...
FDA approves Epidyolex for treatment of tuberous sclerosis complex-associated seizures europeanpharmaceuticalreview
August 04, 2020
Epidyolex, a cannabidiol oral solution, has been given approval by the FDA to treat seizures associated with tuberous sclerosis complex (TSC).
Epidyolex (cannabidiol) reclassified as Schedule 5 in UK, relaxing control over drug europeanpharmaceuticalreview
June 28, 2020
GW Pharmaceuticals’s Epidyolex (cannabidiol) has been changed from a Schedule 2 drug to a Schedule 5 drug, making it exempt from virtually all controlled drug requirements.
Key European committee backs GW's Epidyolex, Bayer's Vitrakvi and more fiercepharma
July 28, 2019
In a busy meeting this week, experts with the European Medicines Agency's Committee for Medicinal Products for Human Use endorsed four new drugs, a Mylan generic, and numerous new indications for already-marketed meds.